Mostrar el registro sencillo del ítem

dc.contributor.authorMolero-Valenzuela, Adrià
dc.contributor.authorFontova Pale, Pere 
dc.contributor.authorAlonso Carrillo, Daniel 
dc.contributor.authorCarreira Barral, Israel 
dc.contributor.authorTorres, Ana Aurora
dc.contributor.authorGarcía Valverde, María 
dc.contributor.authorBenítez-García, Cristina
dc.contributor.authorPérez Tomás, Ricardo
dc.contributor.authorQuesada Pato, Roberto 
dc.contributor.authorSoto Cerrato, Vanessa
dc.date.accessioned2022-07-15T07:25:17Z
dc.date.available2022-07-15T07:25:17Z
dc.date.issued2022-07
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/10259/6766
dc.description.abstractOvercoming resistance is one of the most challenging features in current anticancer therapy. Autophagy is a cellular process that confers resistance in some advanced tumors, since it enables cancer cells to adapt to stressful situations, such as anticancer treatments. Hence, the inhibition of this cytoprotective autophagy leads to tumor cells sensitization and death. In this regard, we designed a novel potent anionophore compound that specifically targets lysosomes, called LAI-1 (late-stage autophagy inhibitor-1), and evaluated its role in blocking autophagy and its potential anticancer effects in three lung cancer cell lines from different histological subtypes. Compared to other autophagy inhibitors, such as chloroquine and 3-Methyladenine, the LAI-1 treatment induced more potent anticancer effects in all tested cancer cells. LAI-1 was able to efficiently target and deacidify lysosomes, while acidifying cytoplasmic pH. Consequently, LAI-1 efficiently blocked autophagy, indicated by the increased LC3-II/I ratio and p62/SQSTM1 levels. Moreover, no colocalization was observed between autophagosomes, marked with LC3 or p62/SQSTM1, and lysosomes, stained with LAMP-1, after the LAI-1 treatment, indicating the blockage of autophagolysosome formation. Furthermore, LAI-1 induced cell death by activating apoptosis (enhancing the cleavage of caspase-3 and PARP) or necrosis, depending on the cancer cell line. Finally, LAI-1 sensitized cancer cells to the first-line chemotherapeutic agent cisplatin. Altogether, LAI-1 is a new late-stage autophagy inhibitor that causes lysosomal dysfunction and the blockage of autophagolysosome formation, as well as potently induces cancer cell death and sensitization to conventional treatments at lower concentrations than other known autophagy inhibitors, appearing as a potential new therapeutic approach to overcome cancer resistance.en
dc.description.sponsorshipThis research was supported by Consejería de Educación de la Junta de Castilla y León (grant BU067P20), MCIN/AEI/10.13039/501100011033 (grant PID2020-117610RB-I00) and Instituto de Salud Carlos III (grant PI18/00441), co-funded by the European Regional Development Fund. ERDF, a way to build Europe. P.F., D.A.-C. and I.C.-B. thank Consejería de Educación de la Junta de Castilla y León, European Social Fund and ERDF for their predoctoral (D.A.-C.) and postdoctoral (P.F. and I.C.-B.) contracts. C.B.-G. thanks the University of Barcelona for a predoctoral fellowship.en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherMDPIes
dc.relation.ispartofCancers. 2022, V. 14, n. 14, 3387es
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAutophagyen
dc.subjectTreatment resistanceen
dc.subjectAutophagy inhibitoren
dc.subjectLysosomal dysfunctionen
dc.subjectAnionophoreen
dc.subjectLung canceren
dc.subjectTreatment sensitizationen
dc.subject.otherMedicinaes
dc.subject.otherMedicineen
dc.subject.otherQuímica orgánicaes
dc.subject.otherChemistry, Organicen
dc.titleA Novel Late-Stage Autophagy Inhibitor That Efficiently Targets Lysosomes Inducing Potent Cytotoxic and Sensitizing Effects in Lung Canceren
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.publisherversionhttps://doi.org/10.3390/cancers14143387es
dc.identifier.doi10.3390/cancers14143387
dc.relation.projectIDinfo:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PID2020-117610RB-I00/ES/SMALL MOLECULE TRANSMEMBRANE ANION CARRIERS FOR BIOLOGICAL APPLICATIONSes
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI18%2F00441/ES/EVALUACION TERAPEUTICA PRECLINICA EN CANCER DE PULMON DE INHIBIDORES DE SURVIVINA MEDIANTE LA UTILIZACION DE FORMULACIONES NANOENCAPSULADAS Y TERAPIAS COMBINADASes
dc.relation.projectIDinfo:eu-repo/grantAgreement/Junta de Castilla y León//BU067P20es
dc.identifier.essn2072-6694
dc.journal.titleCancerses
dc.volume.number14es
dc.issue.number14es
dc.page.initial3387es
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en este ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem